The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: An Italian healthcare payer perspective

被引：0
|
作者：
Patterson, K. [1 ]
Bhattacharyya, S. [1 ]
Personeni, N. [2 ]
Gebbia, V. [3 ]
Novelli, P. [4 ]
Di Matteo, S. [5 ]
Colombo, G. [6 ]
Pescott, C. [7 ]
机构：
[1] BresMed, Hlth Econ, Sheffield, S Yorkshire, England
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] Univ Palermo, La Maddalena Hosp, Palermo, Italy
[4] Merck Serono SpA, HTA & Market Access, Rome, Italy
[5] SAVE Studi Anal Valutaz Econ srl, Hlth Econ & Outcomes Res, Milan, Italy
[6] Univ Pavia, Dept Drug Sci, Pavia, Italy
[7] Merck Healthcare KGaA, Global Evidence & Value Dev, Darmstadt, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
596P
引用
收藏
页码：225 / 225
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer
    Ewara, E. M.
    Zaric, G. S.
    Welch, S.
    Sarma, S.
    CURRENT ONCOLOGY, 2014, 21 (04) : E541 - E550
  • [32] Phase II trial of modified FOLIRI plus Panitumumab as first-line treatment in elderly patients with RAS wild-type metastatic colorectal cancer.
    Karampeazis, Athanasios
    Vamvakas, Lampros
    Kentepozidis, Nikolaos K.
    Kotsakis, Athanasios
    Kalbakis, Kostas
    Xynogalos, Spyros
    Sougklakos, Ioannis
    Emmanouilides, Christos E.
    Voutsina, Alexandra
    Hatzidaki, Dora
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
    Mendez Mendez, Jose Carlos
    Salgado Fernandez, Mercedes
    de la Camara Gomez, Juan
    Pellon Augusto, Mari Luz
    Covela Rua, Marta
    Quintero Aldana, Guillermo
    Fernandez Montes, Ana
    Reboredo Lopez, Margarida
    Valladares Ayerbes, Manuel
    Jorge Fernandez, Monica
    Gonzalez Villarroel, Paula
    Romero Reinoso, Carlos
    Ramos Vazquez, Manuel
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1263 - 1267
  • [34] Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
    Di Nicolantonio, Federica
    Martini, Miriam
    Molinari, Francesca
    Sartore-Bianchi, Andrea
    Arena, Sabrina
    Saletti, Piercarlo
    De Dosso, Sara
    Mazzucchelli, Luca
    Frattini, Milo
    Siena, Salvatore
    Bardelli, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5705 - 5712
  • [35] Clonal selection of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy
    Klein-Scory, S.
    Wahner, I.
    Maslova, M.
    Al-Sewaidi, Y.
    Pohl, M.
    Mika, T.
    Ladigan, S.
    Schroers, R.
    Baraniskin, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S229 - S229
  • [36] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB plus MFOLFOX OVER BEVACIZUMAB plus MFOLFOX AS A FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER PATIENTS WITH WILD-TYPE RAS IN GREECE
    Kourlaba, G.
    Boukovinas, I
    Saridaki, Z.
    Papagiannopoulou, V
    Tritaki, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A633 - A633
  • [37] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Bobo Zheng
    Xin Wang
    Mingtian Wei
    Quan Wang
    Jiang Li
    Liang Bi
    Xiangbing Deng
    Ziqiang Wang
    BMC Cancer, 19
  • [38] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [39] Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States
    Gathirua-Mwangi, Wambui Grace
    Sethi, Harsheen
    Afable, Manuel Geroy
    Bhattacharyya, Devarshi
    Khan, Taha
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1164 - 1172
  • [40] Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
    Lang, Istvan
    Koehne, Claus-Henning
    Folprecht, Gunnar
    Rougier, Philippe
    Curran, Desmond
    Hitre, Erika
    Sartorius, Ute
    Griebsch, Ingolf
    Van Cutsem, Eric
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) : 439 - 448
12345